E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
A Prognostic Model of Therapy-Related Myelodysplastic syndrome .
Hawk Kim,Elias Jabbour,Tapan M. Kadia,Gautam Borthakur,Sherry Pierce,Jianqin Shan,Jorge E. Cortes,Farhad Ravandi,William G. Wierda,Zeev Estrov,Stefan Faderl,Guillermo Garcia-Manero +11 more
TL;DR: Patients that have been previously treated for other malignancies and potential prognostic factors were selected by univariate analyses and validated by multivariate analysis to create a prognostic model of Tx-MDS.
Journal Article
Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study
Utz Krug,Farhad Ravandi,Ellen K. Ritchie,Hamid Sayar,Jeffrey E. Lancet,Craig,Norbert Vey,Stephen A. Strickland,G. J. Schiller,Elias Jabbour,Harry P. Erba,Arnaud Pigneux,H-A Horst,Christian Recher,Virginia M. Klimek,Jorge E. Cortes,Gail J. Roboz,Adam R. Craig,Judith A. Fox,Renee Ward,Jennifer A. Smith,Gary Acton,Cyrus R. Mehta,Hagop M. Kantarjian,Robert K. Stuart +24 more
TL;DR: This paper presents a meta-modelling procedure called “spot-spot analysis” that allows for real-time, 3D image analysis of the response of the immune system to treatment-side effects of chemotherapy.
Journal ArticleDOI
Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.
Maro Ohanian,Farhad Ravandi,Gautam Borthakur,Guillermo Garcia-Manero,Michael Andreeff,Elias Jabbour,Yesid Alvarado,Marina Konopleva,Miranda Lim,Sherry Pierce,Susan O'Brien,Ana Tari Ashizawa,Srdan Verstovsek,William G. Wierda,Jorge E. Cortes +14 more
TL;DR: BP1001 is a liposome-incorporation study of the Growth factor Receptor Bound protein-2 utilized by oncogenic tyrosine kinases to activate Ras and ERK in cancer cell signaling.
Journal ArticleDOI
Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor
Natalia Baran,Alessia Lodi,Yogesh Dhungana,Shannon R. Sweeney,Pandey Renu,Shelley M. Herbrich,Fieke W Hoff,Anna Skwarska,Anna Skwarska,Mecit Kaplan,Vinitha Mary Kuruvilla,Antonio Cavazos,Marc O. Warmoes,Shanti Rojas-Sutterlin,André Haman,Diogo Troggian Veiga,Ken Furudate,Helen Ma,Karine Harutyunyan,Wentao Yang,Mihai Gagea,Di Du,May Daher,Luciana Melo Garcia,Sujan Piya,Vivian Ruvolo,Sriram S. Shanmugavelandy,Ningping Feng,Ondrej Havranek,Jared Henderson,Katarzyna Tomczak,Marcin Kamiński,Daniel Herranz,Adolfo A. Ferrando,Elias Jabbour,Maria Emilia Di Francesco,David T. Teachey,Terzah M. Horton,Katayoun Rezvani,Jun J. Yang,Steven M. Kornblau,Eric Davis,Koichi Takahashi,Michael Andreeff,Joseph R. Marszalek,Philip L. Lorenzi,Jiyang Yu,Stefano Tiziani,Trang Hoang,Marina Konopleva +49 more
TL;DR: It is hypothesized that chemotherapy aided by OxPhos-i overcomes chemoresistance, depletes LSCs and combats T-ALL, as well as targeting key oncogenic and metabolic pathways downstream of mutated NOTCH1 may offer novel approaches.
Journal ArticleDOI
Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)
Jorge E. Cortes,Guillermo Garcia-Manero,Koji Sasaki,Kiran Naqvi,Yesid Alvarado,Tapan M. Kadia,Farhad Ravandi,Jorge E. Cortes,Naval Daver,Koichi Takahashi,Elias Jabbour,Gautam Borthakur,Naveen Pemmaraju,Marina Konopleva,Sherry Pierce,Carlos E. Bueso-Ramos,Keyur P. Patel,Hagop M. Kantarjian,Guillermo Montalban Bravo +18 more
TL;DR: Combination therapy with venetoclax can have activity in patients with R/R MDS but is associated with prolonged myelosuppresion.